At a glance
ClinicalIndex Comparison RecordN/ACompleted· 70 enrolled
Drug / intervention
Atomoxetine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Placebo-controlled Trial of Atomoxetine for Attention Deficit Hyperactivity Disorder in Adolescents With Substance Use Disorder (SUD)
In Brief
A clinical study evaluating Atomoxetine and Placebo for Attention Deficit Hyperactivity Disorder and Substance Abuse. Completed, enrolled 70 participants across 1 site.
Detailed Summary
The purpose of this study is to find out whether atomoxetine (also called Strattera) helps teenagers (12-19) with Attention Deficit Hyperactivity Disorder (ADHD) and drug/alcohol problems.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsAmerican Academy of Child Adolescent Psychiatry.
Timeline
N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2005
First PostedNov 2006
Primary CompletionFeb 2008
TodayJul 2026
First PostedNov 15, 2006
Enrollment StartSep 1, 2005
Primary CompletionFeb 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 19.6 years ago
Interventions
Atomoxetinedrug
Half of participants are randomized to atomoxetine plus individual cognitive behavioral therapy targeting substance use disorder
Placebodrug
Half of participants are randomized to placebo plus individual cognitive behavioral therapy targeting substance use disorder